# A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

> **NCT07681596** · PHASE1,PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 101 (estimated)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** AZD4045
- **DRUG:** Daratumumab
- **DRUG:** Aldesleukin

## Key facts

- **NCT ID:** NCT07681596
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-27
- **Primary completion:** 2031-03-06
- **Final completion:** 2031-03-06
- **Target enrollment:** 101 (ESTIMATED)
- **Last updated:** 2026-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07681596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07681596, "A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07681596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*